GSK

News

Gates Foundation, Wellcome put $550m behind new TB jab

A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t

News

Sanofi sets out plan to lead the RSV vaccine market

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a

News

FDA fast-tracks GSK’s gonorrhoea vaccine

The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on t

News

GSK settles first jury trial in Zantac litigation

GSK has opted to settle a key lawsuit in its defence against claims that its Zantac drug caused cancer, rather than proceed with a jury trial.

News

CDC panel backs use of GSK, Pfizer’s RSV shots this year

Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for

News

FDA delays review of GSK’s momelotinib for myelofibrosis

GSK won’t be hearing from the FDA this month about its marketing application for momelotinib as a treatment for myelofibrosis patients with anaemia after all.

Gates Foundation, Wellcome put $550m behind new TB jab

Sanofi sets out plan to lead the RSV vaccine market

FDA fast-tracks GSK’s gonorrhoea vaccine

GSK settles first jury trial in Zantac litigation

CDC panel backs use of GSK, Pfizer’s RSV shots this year

FDA delays review of GSK’s momelotinib for myelofibrosis

Amgen's Horizon buyout delivers Sjögren's disease win

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks